This is a prospective, double-blind, randomized, and controlled study. The investigational product, DLBS1033 at a dose of 490 mg thrice daily or placebo, will be given for an 8-week course of therapy. DLBS1033 effectively demonstrated fibrinolytic, fibrinogenolytic as well as antithrombotic activities. Hypercoagulation state with high fibrinogen level is usually found in diabetes mellitus patients. Therefore, the hypothesis of interest of this study is that DLBS1033 will reduce fibrinogen level of diabetes mellitus patients better than that of the Control Group.
There will be 2 groups of treatment, each consisting of 68 subjects, with the treatment regimens as the following: Treatment I : DLBS1033 bioactive fraction tablet @ 490 mg, three times daily. Treatment II : Placebo tablet of DLBS1033, three times daily. Clinical examination to evaluate the efficacy of the investigational drug will be performed at baseline and every follow-up visit (at interval of 4 weeks) over the 8 weeks of study period. All subjects will be advised to follow such a lifestyle modification throughout the study period. All subjects will be under direct supervision of a medical doctor during the study period. During the study period, anti-diabetes treatment taken by study subjects should still be continued. Other treatment related to subjects' concomitant illnesses, such as hypertension, and/or dyslipidemia, is allowed during subjects' participation in the study. Other medication such as anti-platelets, fibrinolytic agents and anti-coagulants, or other treatment including herbals/alternatives which may affect haemostatic system, are not allowed to be used during the study period.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
122
1 DLBS1033 tablet 490 mg thrice daily for 2 months
1 placebo tablet of DLBS1033 thrice daily for 2 months
Department of Internal Medicine, Faculty of Medicine, University of Andalas/ dr. M. Djamil Padang Hospital
Padang, West Sumatra, Indonesia
Fibrinogen level reduction
Fibrinogen level reduction from baseline to the end of study (Week 8th)
Time frame: 8 weeks
Change of D-dimer
Change of D-dimer from baseline to every follow-up visit
Time frame: 4 weeks and 8 weeks
Change of von Willebrand Factor activity
Change of von Willebrand Factor activity from baseline to every follow-up visit.
Time frame: 4 weeks and 8 weeks
Change of hs-CRP level
Change of hs-CRP level from baseline to every follow-up visit.
Time frame: 4 weeks and 8 weeks
Change of HbA1c
Change of HbA1c from baseline to end of study (Week 8th).
Time frame: 8 weeks
Liver function
Liver function (serum ALT, AST,γ-glutamyl transferase, alkaline phosphatase) at baseline and end of study (Week 8th)
Time frame: 8 weeks
Renal function
Renal function (serum creatinine, BUN) at baseline and end of study (Week 8th)
Time frame: 8 weeks
Prothrombin Time (PT)
Prothrombin time from baseline to every follow-up visit
Time frame: 4 weeks and 8 weeks
Activated partial thromboplastin time (aPTT)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Activated partial thromboplastin time (aPTT)from baseline to every follow-up visit
Time frame: 4 weeks and 8 weeks
Adverse events
Adverse events (mainly: GI bleeding, and other bleeding events) from baseline to every follow-up visit
Time frame: 4 weeks and 8 weeks (during 8 weeks)
Change of Thromboxane-B2 level
Change of Thromboxane-B2 level from baseline to every follow-up visit (as an indirect indicator to assess the effect of study treatment on TxA2)
Time frame: 4 weeks and 8 weeks